OmicsFootPrint: Mayo Clinic's AI tool offers a new way to visualize disease
Omics is the study of genes, proteins and other molecular data to help uncover how the body functions and how diseases develop. By mapping this data, the OmicsFootPrint may provide clinicians and researchers with a new way to visualize patterns in diseases, such as cancer and neurological disorders, that can help guide personalized therapies. It may also provide an intuitive way to explore disease mechanisms and interactions.
'Data becomes most powerful when you can see the story it's telling,' says lead author Krishna Rani Kalari, Ph.D., associate professor of biomedical informatics at Mayo Clinic's Center for Individualized Medicine. 'The OmicsFootPrint could open doors to discoveries we haven't been able to achieve before.'
Genes act as the body's instruction manual, while proteins carry out those instructions to keep cells functioning. Sometimes, changes in these instructions — called mutations — can disrupt this process and lead to disease. The OmicsFootPrint helps make sense of these complexities by turning data — such as gene activity, mutations and protein levels — into colorful, circular maps that offer a clearer picture of what's happening in the body.
In their study, the researchers used the OmicsFootPrint to analyze drug response and cancer multi-omics data. The tool distinguished between two types of breast cancer — lobular and ductal carcinomas — with an average accuracy of 87%. When applied to lung cancer, it demonstrated over 95% accuracy in identifying two types: adenocarcinoma and squamous cell carcinoma.
The study showed that combining several types of molecular data produces more accurate results than using just one type of data.
The OmicsFootPrint also shows potential in providing meaningful results even with limited datasets. It uses advanced AI methods that learn from existing data and apply that knowledge to new scenarios — a process known as transfer learning. In one example, it helped researchers achieve over 95% accuracy in identifying lung cancer subtypes using less than 20% of the typical data volume.
'This approach could be beneficial for research even with small sample size or clinical studies,' Dr. Kalari says.
To enhance its accuracy and insights, the OmicsFootPrint framework also uses an advanced method called SHAP (SHapley Additive exPlanations). SHAP highlights the most important markers, genes or proteins that influence the results to help researchers understand the factors driving disease patterns.
Beyond research, the OmicsFootPrint is designed for clinical use. It compresses large biological datasets into compact images that require just 2% of the original storage space. This could make the images easy to integrate into electronic medical records to guide patient care in the future.
The research team plans to expand the OmicsFootPrint to study other diseases, including neurological diseases and other complex disorders. They are also working on updates to make the tool even more accurate and flexible, including the ability to find new disease markers and drug targets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 days ago
- Mid East Info
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer
Dubai, United Arab Emirates; June, 2025 — A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA ctDNA— strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma (PDAC). The mutation was identified using a readily available and clinically approved blood and abdominal fluid test. PDAC is an aggressive form of cancer that is often difficult to diagnose. Most patients already have cancer spread to other parts of their body when initially diagnosed, and current tests often miss this hidden spread. This makes it challenging to determine the best treatment strategy. The findings, published in the Annals of Surgical Oncology, may help identify patients who are more likely to have cancer spread to other parts of the body, therefore providing doctors and patients with the right information to make informed decisions about treatment. 'This is a major advancement for pancreatic ductal adenocarcinoma,' says Mark Truty, M.D., hepatobiliary and pancreatic surgical oncologist within Mayo Clinic's Department of Surgery. Dr. Truty is senior author of the study. 'We've had this genetic testing available for a number of years, however, we did not know the significance of the results or how to interpret them. Having the KRAS status will allow the patient and their provider to make better decisions about their individual cancer treatment.' The prospective cohort study, involving nearly 800 patients — the largest patient series to date in the literature using ctDNA — found that 20%-30% of patients with PDAC have detectable mutant KRAS ctDNA in the blood and/or peritoneum, and that those without any previous treatment, such as chemotherapy, had the highest incidence. Thus, the study suggests that ctDNA assays should be performed prior to treatment to have the highest yield. The researchers examined data between 2018 and 2022. Blood sample tests revealed that 104 patients (14%) had KRAS ctDNA mutation. These patients were more likely to develop advanced, spreading cancer and had a lower survival rate. Further testing of fluid from around the abdominal cavity in 419 patients showed similar results: 123 (29%) had the marker, and these patients also experienced worse outcomes. The presence of this marker, whether in blood or abdominal fluid, indicated a poorer prognosis. The study highlights that while surgery is the only known cure, most patients experience cancer spread after surgery. The test helps identify patients less likely to benefit from surgery alone, guiding treatment decisions towards chemotherapy and/or radiation before surgery. For patients without the KRAS mutation (approximately 10% of cases), the test is less conclusive and other tests are needed. 'Historically, we've known that KRAS mutations are associated with a more biologically aggressive pancreatic cancer,' says Jennifer Leiting, M.D., hepatobiliary and pancreatic surgeon within Mayo Clinic's Department of Surgery. Dr. Leiting is first author of the study. 'But this large study gives us a much clearer understanding of how to interpret the test results and use them to improve patient care. It allows for more accurate staging at diagnosis, leading to better treatment decisions.' The researchers suggest that this test should become a standard part of the initial diagnosis for PDAC, enabling more personalized risk stratification and effective treatment plans. 'This improved diagnostic capability offers hope for patients and their families facing this challenging disease,' says Dr. Truty. 'It's optimistic to see how advances in genetic testing are directly helping our patients.'
Mid East Info
7 days ago
- Mid East Info
Mayo Clinic uncovers brain cell changes that could explain Tourette syndrome - Middle East Business News and Information
Dubai, United Arab Emirates; June , 2025 — A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder. The study, published in Biological Psychiatry, is the first to analyze individual brain cells from people with Tourette disorder. The findings also shed light on how different types of brain cells may interact in ways that contribute to the syndrome's symptoms. 'This research may help lay the foundation for a new generation of treatments,' says Alexej Abyzov, Ph.D., a genomic scientist in Mayo Clinic's Center for Individualized Medicine and a co-author of the study. 'If we can understand how these brain cells are altered and how they interact, we may be able to intervene earlier and more precisely.' Tourette disorder is a neurodevelopmental condition that typically begins in childhood. It causes repeated, involuntary movements and vocalizations such as eye blinking, throat clearing or facial grimacing. While genetic studies have identified some risk genes, the biological mechanisms behind the condition have remained unclear. To better understand what's happening in the brain with Tourette syndrome, Dr. Abyzov and his team analyzed more than 43,000 individual cells from postmortem brain tissue of people with and without the condition. They focused on the basal ganglia, a region of the brain that helps control movement and behavior. In each cell, they looked at how genes were working. They also analyzed how changes in the brain's gene-control systems might trigger stress and inflammation. First, they found in people with Tourette syndrome a 50% reduction in interneurons, which are brain cells that help calm excess signals in the brain's movement circuits. They also observed stress responses in two other brain cell types. Medium spiny neurons, which make up most of the cells in basal ganglia and help send movement signals, showed reduced energy production. Microglia, the brain's immune cells, showed inflammation. The two responses were closely linked, suggesting the cells may be interacting in Tourette disorder. 'We're seeing different types of brain cells reacting to stress and possibly communicating with each other in ways that could be driving symptoms,' says Yifan Wang, Ph.D., co-author of the study. The study also provides evidence that the underlying cause of brain cell changes in Tourette disorder may be linked to parts of DNA that control when genes turn on and off. 'Tourette patients seem to have the same functional genes as everyone else but the coordination between them is broken,' Dr. Abyzov says. Next, the researchers plan to study how these brain changes develop over time and look for genetic factors that may help explain the disorder. The study was conducted in collaboration with the lab of Flora M. Vaccarino, M.D., at Yale University. For a complete list of authors, disclosures and funding, review the study.
Mid East Info
10-06-2025
- Mid East Info
New Mayo Venture Partner (MVP) program announced to accelerate innovation - Middle East Business News and Information
Dubai, United Arab Emirates; June, 2025 — Mayo Clinic's Business Development team, consistently recognized as one of the top commercialization operations among academic medical centers, is expanding its capabilities through a new initiative: the Mayo Venture Partner (MVP) program. In response to the dynamic and evolving healthcare landscape, Mayo Clinic is enlisting industry veterans to create groundbreaking technologies, co-invest in aligned companies and build new ventures from the ground up. The MVP program brings together seasoned entrepreneurs, investors and executives who will leverage their expertise with Mayo Clinic's world-class research and clinical expertise. These leaders will play a pivotal role in identifying high-potential opportunities across Mayo Clinic's research and clinical practices, forming new companies and accelerating innovations that advance patient care. The inaugural MVPs are: Amy DuRoss — Healthcare innovation leader with deep expertise in policy, commercialization and diagnostics. Audrey Greenberg — Company builder, executive leader and expert in launching and scaling ventures across life sciences, healthcare and other industries. Brian Poger — Serial entrepreneur and venture strategist with a track record in digital health and healthcare services. Working in close partnership with the Mayo Clinic Business Development team, the MVPs will help forge strategic collaborations and deliver real-world impact, underscoring Mayo Clinic's enduring commitment to transforming healthcare. To date, the Business Development team has returned more than $1.2B in revenue to Mayo Clinic to support its clinical practice, education and research. Additionally, the team has helped create more than 180 companies, licensed 4,848 Mayo Clinic-created technologies through 2,913 agreements, and issued 4,159 patents. This program and these efforts align with Mayo Clinic's vision to transform healthcare by: Accelerating innovation — Turning cutting-edge research, data and other resources into real-world solutions for patients. Enhancing patient care — Bringing new treatments and technologies to patients that offer cures and the ability to connect with the healthcare system in ways that increase access and decrease costs. Building strategic partnerships — Leveraging external expertise and resources to amplify impact. Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting opportunity for investors, CEOs and innovators to collaborate with Mayo Clinic and be part of a future that prioritizes patient-centric, transformative healthcare solutions. To learn more, visit the Mayo Clinic Business Development website and subscribe to its e-newsletter and follow the Mayo Clinic Ventures LinkedIn page.
